Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 4 of 6351
-
Can a Pre-Surgery drug combo wipe out early lung cancer?
Cure Not yet recruitingThe study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of sur…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Pig kidney trial offers hope to thousands waiting for transplants
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation…
Phase 1/2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
Cure Not yet recruitingPhase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Cure
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells take down advanced prostate cancer?
Cure Not yet recruitingThis phase I trial tests the safety, side effects, best dose and how well giving IL-18 armored STEAP1 CAR T cells after lymphodepleting chemotherapy (with cyclophosphamide and fludarabine) works for the treatment of castration resistant prostate cancer that has spread from where …
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Cure
Last updated Sep 06, 2026 00:00 UTC
-
Can a Two-Drug combo outperform standard care in aggressive lung cancer?
Disease control Not yet recruitingThis trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Brain implant aims to give voice to those trapped in silence
Disease control Not yet recruitingEighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals…
Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingResearchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a smart drug outsmart pancreatic cancer?
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer patients who have failed prior Gemcitabine-based sys…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingSystemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs. The disease can affect the skin, joints, kidneys, blood cells, brain, and other organs, leading to significant health problems and r…
Phase 1/2 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could MDMA help heal PTSD in soldiers? new trial investigates
Disease control Not yet recruitingThis study is a Phase 2, randomized, double-blind, active-controlled, two-arm, single-site clinical trial designed to evaluate the safety, tolerability, and feasibility of MDMA-Assisted Therapy (MDMA-AT) for Service Members (Active Duty, Guard, or Reserve) diagnosed with moderate…
Phase 2 • Sponsor: U.S. Army Medical Research and Development Command • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a single gene therapy turn the body into a Cancer-Fighting factory?
Cure Not yet recruitingThis study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.
Phase 1 • Sponsor: Umoja Biopharma • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can a simple Self-Test cut preterm births in High-Risk pregnancies?
Prevention Not yet recruitingPreterm birth is a major cause of mortality and long-term disability. Bacterial vaginosis (BV) is a frequent form of dysbiosis that is often asymptomatic and increases the risk of preterm birth. BV is usually diagnosed using conventional tools such as the Nugent score. Molecular …
Phase 3 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
Can a temporary heart pump save more lives in cardiogenic shock?
Disease control Not yet recruitingThe goal of this clinical trial is to learn which treatment strategies improve survival in adult patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The main questions it aims to answer are: * Does the immediate use of a left-sided microaxial fl…
Sponsor: Leipzig Heart Science gGmbH • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new combo drug tame childhood leukemia that Won't quit?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment or has not responded to treatment. The study will …
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Personalized drug matching put to the test in pancreatic cancer
Disease control Not yet recruitingPancreatic cancer that has spread or cannot be removed by surgery is difficult to treat. Standard chemotherapy can slow the disease, but the cancer often starts growing again. Some pancreatic cancers have specific genetic changes that may be targeted by medicines already availabl…
Phase 2 • Sponsor: Herlev Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug duo aims to outsmart EGFR-mutant lung cancer
Disease control Not yet recruitingThe purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherap…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
Cure Not yet recruitingThis Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory lupus nephritis who are not resp…
Phase 2 • Sponsor: AbelZeta Inc. • Aim: Cure
Last updated Jul 30, 2026 00:00 UTC
-
Can transplanted cells restore insulin production in type 2 diabetes?
Cure Not yet recruitingThis Phase I clinical trial is a multi-center, single-arm, open-label study aimed at evaluating the safety and efficacy of RGB-5088 islet cell infusion in patients with Type 2 Diabetes Mellitus.
Phase 1 • Sponsor: Hangzhou Reprogenix Bioscience, Inc • Aim: Cure
Last updated Sep 09, 2026 15:00 UTC
-
Can a daily injection restore hand function after spinal cord injury?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and dai…
Phase 3 • Sponsor: NervGen Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a targeted drug keep ovarian cancer at bay longer?
Disease control Not yet recruitingResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance trea…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC